<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>21(22)</volume><submitter>Chen H</submitter><pubmed_abstract>MTH1 (MutT homolog 1) or NUDT1 (Nudix Hydrolase 1), also known as oxidized purine nucleoside triphosphatase, has potential as a biomarker for monitoring cancer progression and quantifying target engagement for relevant therapies. In this study, we validate one MTH1 inhibitor TH287 as a PET MTH1 radiotracer. TH287 was radiolabeled with tritium and the binding of [3H]TH287 to MTH1 was evaluated in live glioblastoma cells (U251MG) through saturation and competitive binding assays, together with in vitro enzymatic assays. Furthermore, TH287 was radiolabeled with carbon-11 for in vivo microPET studies. Saturation binding assays show that [3H]TH287 has a dissociation constant (Kd) of 1.97 ± 0.18 nM, Bmax of 2676 ± 122 fmol/mg protein for U251MG cells, and nH of 0.98 ± 0.02. Competitive binding a</pubmed_abstract><journal>International journal of molecular sciences</journal><pagination>E8860</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7700685</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1.</pubmed_title><pmcid>PMC7700685</pmcid><pubmed_authors>Rogers BE</pubmed_authors><pubmed_authors>Guo Y</pubmed_authors><pubmed_authors>Perlmutter JS</pubmed_authors><pubmed_authors>Chu W</pubmed_authors><pubmed_authors>Garbow JR</pubmed_authors><pubmed_authors>Zhou D</pubmed_authors><pubmed_authors>Chen H</pubmed_authors><pubmed_authors>Benzinger TLS</pubmed_authors><pubmed_authors>Afrin S</pubmed_authors><pubmed_authors>Xu J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1.</name><description>MTH1 (MutT homolog 1) or NUDT1 (Nudix Hydrolase 1), also known as oxidized purine nucleoside triphosphatase, has potential as a biomarker for monitoring cancer progression and quantifying target engagement for relevant therapies. In this study, we validate one MTH1 inhibitor TH287 as a PET MTH1 radiotracer. TH287 was radiolabeled with tritium and the binding of [3H]TH287 to MTH1 was evaluated in live glioblastoma cells (U251MG) through saturation and competitive binding assays, together with in vitro enzymatic assays. Furthermore, TH287 was radiolabeled with carbon-11 for in vivo microPET studies. Saturation binding assays show that [3H]TH287 has a dissociation constant (Kd) of 1.97 ± 0.18 nM, Bmax of 2676 ± 122 fmol/mg protein for U251MG cells, and nH of 0.98 ± 0.02. Competitive binding a</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2025-05-29T19:16:47.965Z</modification><creation>2024-11-05T20:19:31.976Z</creation></dates><accession>S-EPMC7700685</accession><cross_references><pubmed>33238630</pubmed><doi>10.3390/ijms21228860</doi></cross_references></HashMap>